Clinical trials: Neovascular Age-Related Macular Degeneration (nAMD), open to volunteers
Neovascular Age-Related Macular Degeneration (nAMD)
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
This Phase 3 study is evaluating the safety and efficacy of 4D-150 versus aflibercept in participants with neovascular age-related macular degeneration (nAMD).
- Trial name
- 4FRONT-2 (NCT07064759)
- Testing
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 126 sites in United States, Argentina and 15 more
- Volunteers
- 480 people
- Sponsor
- 4D Molecular Therapeutics
Neovascular Age-related Macular Degeneration, nAMD
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular…
- Trial name
- NCT07614776
- Testing
- ABP 938 8 mg, Aflibercept (US) 8 mg
- Where
- 81 sites in United States, Czechia and 7 more
- Volunteers
- 304 people
- Sponsor
- Amgen
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- AQUARIUS (NCT07482176)
- Testing
- Ixo-vec, Aflibercept
- Where
- 79 sites in United States
- Volunteers
- 534 people
- Sponsor
- Adverum Biotechnologies, Inc.
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
This is a Phase I, multicenter, open-label, dose-escalation study conducted in two parts to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GenSci148 administered via intravitreal (IVT)…
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
- Trial name
- GenSci148-101 (NCT07817615)
- Testing
- GenSci148 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Neovascular Age Related Macular Degeneration(nAMD)
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- ASCEND (NCT07798375)
- Testing
- VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration
- Volunteers
- 244 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
This is a Phase II, randomized, open-label, active-controlled study designed to evaluate the preliminary efficacy and safety of a single subretinal administration of JWK001 at different dose levels in patients with neovascular…
- Trial name
- NCT07776522
- Testing
- JWK001, Aflibercept (2.0 mg)
- Where
- 16 sites in China
- Volunteers
- 50 people
- Sponsor
- West China Hospital
Neovascular Age-related Macular Degeneration(nAMD), Wet Macular Degeneration
LEAP Strategy for Neovascular Age-Related Macular Degeneration
Background: Age-related macular degeneration (AMD) is a common eye disease that can cause blindness in older adults. The "wet" form of AMD, called neovascular AMD, happens when abnormal blood vessels grow under the retina and…
- Trial name
- LEAP (NCT07744204)
- Testing
- Laser photocoagulation, Anti-VEGF agents
- Volunteers
- 240 people
- Sponsor
- Chinese PLA General Hospital
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration.
- Trial name
- NCT07317934
- Testing
- LX102, Aflibercept
- Where
- 36 sites in China
- Volunteers
- 388 people
- Sponsor
- Innostellar Biotherapeutics Co.,Ltd
Neovascular Age-Related Macular Degeneration (nAMD)
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD in which they received suprachoroidal…
- Trial name
- NCT05210803
- Testing
- Standard of Care, Ranibizumab
- Where
- 16 sites in United States
- Volunteers
- 116 people
- Sponsor
- AbbVie
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
The purpose of this study is to evaluate safety, effectiveness and durability of a gene therapy called Ixo-vec (Ixoberogene soroparvovec) when administered to the contralateral (second) eye of adult participants (≥ 50 years of…
- Trial name
- NCT07630649
- Testing
- Ixo-vec
- Where
- 12 sites in United States
- Volunteers
- 15 people
- Sponsor
- Adverum Biotechnologies, Inc.
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients
Primary objective: To evaluate the change in aqueous humor vascular endothelial growth factor A (VEGF-A) levels after 2 months of initial treatment with 8 mg Aflibercept in treatment-naïve nAMD patients.
- Trial name
- NCT07728981
- Testing
- Aflibercept 8mg
- Volunteers
- 49 people
- Sponsor
- Tianjin Medical University Eye Hospital
Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
- Trial name
- NCT07516132
- Testing
- OTX-TKI
- Where
- 8 sites in United States
- Volunteers
- 850 people
- Sponsor
- Ocular Therapeutix, Inc.
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are: nAMD (neovascular age-related macular degeneration): a condition that…
- Trial name
- NCT07308639
- Testing
- anti-VEGF medication
- Where
- Germany
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Neovascular Age-Related Macular Degeneration (nAMD)
Real-world Study of Aflibercept 8 mg in nAMD
The goal of this observational study is to explore the effectiveness of aflibercept 8 mg in treating both treatment-naive and previously treated patients with neovascular age-related macular degeneration (nAMD) in a real-world…
- Trial name
- NCT07640997
- Testing
- Aflibercept 8mg
- Where
- 27 sites in China
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Neovascular Age-related Macular Degeneration(nAMD)
Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)
Evaluate the benefit of faricimab (4 loading doses + PRN) on best-corrected visual acuity in patients with nAMD. Evaluate the safety and anatomical improvement of faricimab (4 loading doses + PRN) in patients with nAMD.
- Trial name
- NCT07581782
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Neovascular Age-Related Macular Degeneration (nAMD)
A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration
The goal of this clinical trial is to evaluate the efficacy and safety of QL1207H injection versus aflibercept 8 mg in patients with neovascular age-related macular degeneration.
- Trial name
- NCT07489586
- Testing
- QL1207H injection, Aflibercept 8 mg
- Volunteers
- 356 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
This study aims to preliminarily evaluate the efficacy and safety of GB10 intravitreal (IVT) injection for the treatment of patients with neovascular age-related macular degeneration (nAMD).
- Trial name
- NCT07406438
- Testing
- GB10
- Where
- 6 sites in China
- Volunteers
- 48 people
- Sponsor
- Shenzhen Kexing Pharmaceutical Co., Ltd.
Neovascular Age-related Macular Degeneration(nAMD)
Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD) is one of the main causes of irreversible vision loss in the elderly, characterized by neovascularization and vascular leakage in the macular area, ultimately leading to damage…
- Trial name
- NCT07088445
- Testing
- Faricimab
- Volunteers
- 35 people
- Sponsor
- Hui Peng
Neovascular Age-related Macular Degeneration (nAMD)
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related…
- Trial name
- NCT06470373
- Testing
- RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection
- Where
- 7 sites in United States
- Volunteers
- 434 people
- Sponsor
- Rophibio, Inc.
Neovascular Age-related Macular Degeneration(nAMD)
CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
Age-related macular degeneration (AMD) is a progressive disease leading to severe and irreversible vision loss of which the neovascular AMD (nAMD) accounted for 90% blindness in AMD.
- Trial name
- NCT06031727
- Testing
- HG202
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- HuidaGene Therapeutics Co., Ltd.